Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

التفاصيل البيبلوغرافية
العنوان:	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
المؤلفون:	Pulsipher MA; Section of Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. michael.pulsipher@hci.utah.edu., Han X; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Maude SL; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania., Laetsch TW; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.; Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas., Qayed M; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.; Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia., Rives S; Pediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain., Boyer MW; Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah., Hiramatsu H; Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan., Yanik GA; Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children's Hospital, Ann Arbor, Michigan., Driscoll T; Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina., Myers GD; Pediatric Hematology and Oncology, Children's Mercy Hospital; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri., Bader P; Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany., Baruchel A; Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France.; Université de Paris et Institut de Recherche Saint-Louis (EA3518), Paris, France., Buechner J; Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway., Stefanski HE; Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota., Kalfoglou C; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Nguyen K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Waldron ER; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Thudium Mueller K; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey., Maier HJ; Novartis Pharmaceuticals Corporation, Basel, Switzerland., Kari G; Novartis Pharmaceuticals Corporation, Basel, Switzerland., Grupp SA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
المصدر:	Blood cancer discovery [Blood Cancer Discov] 2022 Jan; Vol. 3 (1), pp. 66-81. Date of Electronic Publication: 2021 Dec 01.
نوع المنشور:	Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة:	English
بيانات الدورية:	Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101764786 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2643-3249 (Electronic) Linking ISSN: 26433230 NLM ISO Abbreviation: Blood Cancer Discov Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Philadelphia, PA : American Association for Cancer Research, [2020]-
مواضيع طبية MeSH:	Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis, Antigens, CD19 ; Child ; High-Throughput Nucleotide Sequencing ; Humans ; Neoplasm, Residual/genetics ; Receptors, Antigen, T-Cell ; Recurrence ; Young Adult
مستخلص:	We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse ( N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within the first year of treatment was associated with a hazard ratio (HR) for relapse of 4.5 [95% confidence interval (CI), 2.03-9.97; P < 0.001]. Multivariate analysis at day 28 showed independent associations of BMNGS-MRD >0 (HR = 4.87; 95% CI, 2.18-10.8; P < 0.001) and B-cell recovery (HR = 3.33; 95% CI, 1.44-7.69; P = 0.005) with relapse. By 3 months, the BMNGS-MRD HR increased to 12 (95% CI, 2.87-50; P < 0.001), whereas B-cell recovery was not independently predictive (HR = 1.27; 95% CI, 0.33-4.79; P = 0.7). Relapses occurring with persistence of B-cell aplasia were largely CD19 ^- (23/25: 88%). Detectable BMNGS-MRD reliably predicts risk with sufficient time to consider approaches to relapse prevention such as hematopoietic cell transplantation (HCT) or second CAR-T cell infusion. SIGNIFICANCE: Detectable disease by BMNGS-MRD with or without B-cell aplasia is highly predictive of relapse after tisagenlecleucel therapy for ALL. Clonotypic rearrangements used to follow NGS-MRD did not change after loss of CD19 or lineage switch. High-risk patients identified by these biomarkers may benefit from HCT or investigational cell therapies. See related commentary by Ghorashian and Bartram, p. 2 . This article is highlighted in the In This Issue feature, p. 1 . (©2021 The Authors; Published by the American Association for Cancer Research.)
التعليقات:	Comment in: Blood Cancer Discov. 2022 Jan;3(1):2-4. (PMID: 35019857)
References:	BMC Cancer. 2020 Jun 30;20(1):612. (PMID: 32605647) Blood. 2017 Jun 22;129(25):3322-3331. (PMID: 28408462) Blood. 2018 Mar 22;131(12):1350-1359. (PMID: 29284596) Blood. 2012 Dec 20;120(26):5173-80. (PMID: 23074282) J Clin Oncol. 2015 Apr 10;33(11):1275-84. (PMID: 25605857) Blood. 2014 Mar 27;123(13):2017-25. (PMID: 24497539) J Clin Oncol. 2008 Jun 20;26(18):3046-50. (PMID: 18565891) Leukemia. 2021 Dec;35(12):3383-3393. (PMID: 34002027) N Engl J Med. 2013 Apr 18;368(16):1509-1518. (PMID: 23527958) Cancer Discov. 2015 Dec;5(12):1282-95. (PMID: 26516065) N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370) Leukemia. 2018 Nov;32(11):2316-2325. (PMID: 29728694) J Clin Oncol. 2021 Mar 10;39(8):920-930. (PMID: 33417474) Blood Adv. 2020 May 26;4(10):2325-2338. (PMID: 32453841) N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870) Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. (PMID: 30190371) Blood. 2019 Apr 11;133(15):1652-1663. (PMID: 30728140) Blood Adv. 2019 Nov 12;3(21):3393-3405. (PMID: 31714961) Blood. 2010 Apr 22;115(16):3206-14. (PMID: 20154213) Nat Med. 2018 Oct;24(10):1504-1506. (PMID: 30275569) J Clin Oncol. 2021 May 20;39(15):1650-1659. (PMID: 33764809) Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S71-4. (PMID: 18545248) Blood. 2015 Aug 20;126(8):964-71. (PMID: 26124497) Blood. 2015 May 28;125(22):3501-8. (PMID: 25862561) J Clin Oncol. 2009 Jan 20;27(3):377-84. (PMID: 19064980)
معلومات مُعتمدة:	T32 HL007950 United States HL NHLBI NIH HHS
المشرفين على المادة:	0 (Antigens, CD19) 0 (Receptors, Antigen, T-Cell) Q6C9WHR03O (tisagenlecleucel)
تواريخ الأحداث:	Date Created: 20220112 Date Completed: 20220505 Latest Revision: 20230215
رمز التحديث:	20230215
مُعرف محوري في PubMed:	PMC9924295
DOI:	10.1158/2643-3230.BCD-21-0095
PMID:	35019853
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	2643-3249
DOI:	10.1158/2643-3230.BCD-21-0095